Related Experiment Video
Updated: Jun 9, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case
Sho Shimasaki1, Shinkuro Yamamoto1, Mitsuko Iguchi2
1Department of Urology Kochi Medical School, Kochi University Nankoku Kochi Japan.
Introduction:
Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare renal cell carcinoma subtype that is typically indolent but may exhibit aggressive behavior. No standard systemic therapy has been established for metastatic MTSCC.
Case Presentation:
A 71-year-old woman underwent retroperitoneoscopic radical left nephrectomy for MTSCC (pT1b). Six months later, computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography (PET)/CT revealed lung, bone, and adrenal metastases. Bone biopsy confirmed metastatic MTSCC, and the patient was classified as poor risk. Combination therapy with nivolumab and ipilimumab was initiated. After two cycles, PET/CT showed marked regression of metastatic lesions (SUVmax decreased from 21.7 to 4.3). RECIST evaluation demonstrated a partial response. Genomic profiling revealed microsatellite stability and a low tumor mutational burden, with no clinically actionable alterations identified on FoundationOne CDx. No disease progression was observed at 9 months.
Conclusion:
This case demonstrates the potential efficacy of combination immunotherapy in aggressive metastatic MTSCC.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013